SAB Bio Wins FDA Fast Track for Diabetes Drug

SAB Biotherapeutics has won FDA Fast Track designation for SAB-142, a fully human antibody therapy manufactured not in a bioreactor or a donor's plasma but in a herd of genetically engineered cattle. The Miami Beach company announced the designation on 13 October 2026 for newly diagnosed Stage 3 type 1 diabetes — the disease stage after clinical onset, where SAB-142 is betting it can still change the course of autoimmune destruction already under way.

SAFEGUARD by the numbers

159patients targeted across the Phase 2b SAFEGUARD trial

100 daysthe window after diagnosis to enroll in the pivotal study

60+trial sites across the U.S., Australia, New Zealand, the U.K. and the E.U.

2H 2027topline data expected, after enrollment completes in Q4 2026

Figures from SAB Biotherapeutics' public disclosures and the SAFEGUARD trial record (NCT07187531).

A cattle herd instead of a plasma bank

Most antibody therapies begin with either a human donor or a genetically engineered mouse. SAB Biotherapeutics' DiversitAb platform begins with cattle. The company breeds transchromosomic bovines — animals carrying an engineered human artificial chromosome — so that when they are immunized against a target, their immune systems produce fully human antibodies rather than bovine ones. SAB's own SEC filings describe the approach as a way to generate human polyclonal antibodies at scale without recruiting human donors, screening plasma, or relying on a single monoclonal target.

SAB-142 applies that platform to type 1 diabetes. It is a fully human anti-thymocyte immunoglobulin — an hATG, in the shorthand regulatory readers will recognize from transplant medicine, where rabbit- or horse-derived ATG has depleted T cells for decades. SAB's version swaps the animal-derived serum for a human one, aimed specifically at the T cells that attack and destroy insulin-producing beta cells in the pancreas. The company's announcement frames Fast Track designation, which speeds FDA review and allows more frequent agency contact without lowering the evidence bar, as recognition that SAB-142 may address a condition with no fully satisfactory treatment once diagnosis has already occurred.

“…an important regulatory milestone for SAB-142…” — reflecting, Reich said, the FDA’s view that the program may address an unmet medical need in type 1 diabetes. Samuel J. Reich, Chairman and CEO, SAB Biotherapeutics — 13 October 2026 announcement

Why Stage 3, not Stage 2

The one disease-modifying immunotherapy FDA has approved for type 1 diabetes, Sanofi's Tzield (teplizumab), works upstream: it is given at Stage 2, before a patient has any clinical symptoms, to delay the onset of Stage 3 disease in people identified through autoantibody screening. SAB-142 is built for the other side of that line — patients already diagnosed with Stage 3 disease, within 100 days of diagnosis, while some beta-cell function typically still remains. That is a larger, easier-to-identify population than the pre-symptomatic Stage 2 group Tzield targets, but it is also a harder biological problem: the autoimmune attack is already established rather than merely anticipated.

Three things that separate SAB-142 from the one approved rival

01

A different moment to intervene

Tzield delays onset before diagnosis; SAB-142 is dosed after diagnosis, aiming to preserve whatever beta-cell function remains rather than postpone a diagnosis that has already happened.

02

A polyclonal mechanism, not one monoclonal target

Tzield is a single anti-CD3 monoclonal antibody. SAB-142 is a polyclonal hATG, depleting T cells more broadly — the same general approach transplant medicine has used for decades, now made from fully human antibodies instead of rabbit or horse serum.

03

A regulatory shortcut already banked

SAB has said FDA correspondence has confirmed that C-peptide, a measure of remaining insulin production, may serve as a surrogate endpoint supporting accelerated approval — a marker the company can read out well before a full clinical-outcomes trial would mature.

What a disease-modifying label is worth

Tzield's launch is the clearest guide to what a second disease-modifying entrant could be worth. GlobalData, the research firm, has forecast Tzield sales reaching $3.8 billion by 2031 and $4.8 billion across the seven major pharmaceutical markets by 2033 — even though the firm has also noted Tzield's sales ran at only about 1.2% of total type 1 diabetes drug spending in 2023, a sign of how slowly a genuinely new category can build against decades of insulin-centric practice. SAB-142 is not chasing the same patients Tzield treats, which complicates a head-to-head comparison but also means the two drugs' commercial fates are not a zero-sum contest for the same prescription.

What one disease-modifying label has already shown

$3.8B → $4.8B

GlobalData's published forecasts for Sanofi's Tzield, the only approved disease-modifying type 1 diabetes immunotherapy, by 2031 and across the seven major markets by 2033.

2023 actual~1.2% of T1D drug sales

2031 (U.S.)$3.8B

2033 (7MM)$4.8B

Sources: GlobalData, Tzield (teplizumab) sales forecasts

Regulatory News outlook

If SAB-142 clears SAFEGUARD, we expect it to open a second, comparably sized disease-modifying category in type 1 diabetes rather than take share directly from Tzield, since the two drugs are aimed at different moments in the disease.

How we got here: We treat GlobalData's $3.8 billion 2031 Tzield forecast as a proxy for a single disease-modifying T1D drug's ceiling in one major market, and note that a second approved mechanism aimed at a different, larger eligible population (post-diagnosis Stage 3, rather than pre-diagnosis Stage 2) plausibly supports a comparable, additive figure rather than splitting the existing one; we do not assign SAB-142 its own dollar estimate before Phase 2b data exist.

Two ways to modify type 1 diabetes, not one race

Product	Mechanism	Disease stage	Dosing	Status
SAB-142 (SAB Biotherapeutics)	Fully human polyclonal hATG, T-cell depletion	Stage 3, within 100 days of diagnosis	Two infusions, six months apart	Phase 2b SAFEGUARD, FDA Fast Track
Tzield (Sanofi)	Anti-CD3 monoclonal antibody	Stage 2, before clinical onset	14 daily infusions, one course	FDA-approved, November 2022
Zimislecel / VX-880 (Vertex)	Stem-cell-derived islet cell replacement	Established Stage 3 disease	Infused cell therapy with immunosuppression	Phase 1/2

From each company’s own labelling and public disclosures; not a clinical comparison.

From a South Dakota antibody lab to Fast Track

SAB-142's path to Fast Track

1. 2014

   SAB Biotherapeutics founded

   Grew out of antibody research at the University of South Dakota, building what became the DiversitAb transchromosomic-cattle platform.

2. 2021

   Nasdaq listing

   SAB completed its public listing as SABS, having previously developed antibody candidates for infectious disease.

3. December 2025

   First patient dosed

   The registrational Phase 2b SAFEGUARD trial dosed its first SAB-142 patient.

4. 13 October 2026

   FDA Fast Track designation

   Granted for SAB-142 in new-onset Stage 3 type 1 diabetes.

5. Q4 2026

   SAFEGUARD enrollment to complete

   Across more than 60 sites in five countries, targeting 159 patients.

6. 2H 2027

   Topline data expected

   The readout that will determine whether SAB-142 advances toward an accelerated approval filing.

What Fast Track does not settle

Fast Track designation is a process accommodation, not a verdict on SAB-142's chances. It buys SAB more frequent FDA meetings and the option to submit a Biologics License Application in sections as data mature, rather than all at once — valuable for a small company managing a multi-year registrational trial, but silent on whether SAB-142 actually preserves beta-cell function at the rate its Phase 1 data suggested. A separate, investigator-led Phase 3 study, PRISE-hATG, is now testing SAB-142 further out from diagnosis — 100 days to two years post-diagnosis — with support from a Breakthrough T1D research grant, widening the population the drug might eventually serve if SAFEGUARD succeeds.

• Enrollment: SAFEGUARD Part B and Part C target 159 patients ages 5–40, due to complete enrollment in Q4 2026.
• Readout: Topline data expected in the second half of 2027 — the trial result that will determine whether SAB-142 moves toward a regulatory filing.
• Regulatory runway: SAB has said FDA correspondence supports using C-peptide, a surrogate marker of remaining insulin production, toward a possible accelerated approval pathway.
• Wider population: The separate PRISE-hATG study, backed by a Breakthrough T1D grant, is testing SAB-142 in patients 100 days to two years past diagnosis — outside SAFEGUARD's narrower window.

What the 13 October announcement does not state: a Biologics License Application timeline, or any protection against the risk every antibody-depletion therapy carries — infection and other effects of broadly suppressing T cells, which SAFEGUARD's safety data will need to characterize fully before any filing. Regulatory News will update this page as SAFEGUARD's enrollment and safety data are published.

Frequently asked questions

What did FDA grant SAB Biotherapeutics?

Fast Track designation for SAB-142, announced 13 October 2026, for new-onset Stage 3 type 1 diabetes. Fast Track speeds development and review — more frequent FDA contact, rolling submission eligibility — but does not change the evidence SAB-142 must show, and does not guarantee approval.

What is SAB-142?

A fully human anti-thymocyte immunoglobulin (hATG) made on SAB's DiversitAb platform: genetically engineered cattle carrying a human artificial chromosome produce human antibodies without any human donor or plasma. SAB-142 is designed to deplete the T cells that destroy insulin-producing beta cells.

Who can enroll in the SAFEGUARD trial?

People within 100 days of a Stage 3 type 1 diabetes diagnosis, ages 5 to 40. The registrational Phase 2b trial (NCT07187531) targets 159 patients across more than 60 sites in the United States, Australia, New Zealand, the United Kingdom and the European Union, dosed with two infusions six months apart.

How is this different from Tzield?

Sanofi's Tzield (teplizumab), approved in 2022, is given to Stage 2 patients — before clinical onset — to delay progression to Stage 3. SAB-142 is aimed at people already diagnosed with Stage 3 disease, using a different, polyclonal antibody mechanism rather than Tzield's single anti-CD3 monoclonal antibody.